These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 38194741)

  • 21. Successful treatment of methotrexate intolerance in juvenile idiopathic arthritis using eye movement desensitization and reprocessing - treatment protocol and preliminary results.
    Höfel L; Eppler B; Storf M; Schnöbel-Müller E; Haas JP; Hügle B
    Pediatr Rheumatol Online J; 2018 Feb; 16(1):11. PubMed ID: 29433504
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of subcutaneous administration of methotrexate in children with juvenile idiopathic arthritis who have failed oral methotrexate.
    Alsufyani K; Ortiz-Alvarez O; Cabral DA; Tucker LB; Petty RE; Malleson PN
    J Rheumatol; 2004 Jan; 31(1):179-82. PubMed ID: 14705239
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of and factors associated to chronic kidney disease and hypertension in a cohort of children with juvenile idiopathic arthritis.
    Gicchino MF; Di Sessa A; Guarino S; Miraglia Del Giudice E; Olivieri AN; Marzuillo P
    Eur J Pediatr; 2021 Feb; 180(2):655-661. PubMed ID: 32860100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictors of the response to etanercept in patients with juvenile idiopathic arthritis without systemic manifestations within 12 months: results of an open-label, prospective study conducted at the National Scientific and Practical Center of Children's Health, Russia.
    Alexeeva EI; Namazova-Baranova LS; Bzarova TM; Valieva SI; Denisova RV; Sleptsova TV; Isaeva KB; Chomahidze AM; Taibulatov NI; Fetisova AN; Karaseva AV; Baranov AA
    Pediatr Rheumatol Online J; 2017 Jun; 15(1):51. PubMed ID: 28615036
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Increased methotrexate intolerance in juvenile idiopathic arthritis compared to acute lymphoblastic leukaemia in children.
    Kyvsgaard N; Mikkelsen TS; Thastum M; Christensen AE; Wehner PS; Nysom K; Herlin T
    PLoS One; 2019; 14(7):e0219539. PubMed ID: 31295288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial.
    Hissink Muller P; Brinkman DMC; Schonenberg-Meinema D; van den Bosch WB; Koopman-Keemink Y; Brederije ICJ; Bekkering PW; Kuijpers TW; Van Rossum M; van Suijlekom-Smit LWA; van den Berg JM; Boehringer S; Allaart CF; Ten Cate R
    Ann Rheum Dis; 2019 Jan; 78(1):51-59. PubMed ID: 30309970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Factors associated with improvement in disease activity following initiation of etanercept in children and young people with Juvenile Idiopathic Arthritis: results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study.
    Kearsley-Fleet L; Davies R; Lunt M; Southwood TR; Hyrich KL
    Rheumatology (Oxford); 2016 May; 55(5):840-7. PubMed ID: 26721878
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
    Beukelman T; Lougee A; Matsouaka RA; Collier D; Rumsey DG; Schenfeld J; Stryker S; Twilt M; Kimura Y;
    Pediatr Rheumatol Online J; 2021 Aug; 19(1):131. PubMed ID: 34419107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Perceptions of Methotrexate Intolerance and Its Impact on Daily Life in School-Age Children with Juvenile Idiopathic Arthritis.
    Khan S; Mancini J; Hopper C; Rennick JE
    J Pediatr Nurs; 2019; 48():49-54. PubMed ID: 31254860
    [TBL] [Abstract][Full Text] [Related]  

  • 30. S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis.
    Gohar F; Anink J; Moncrieffe H; Van Suijlekom-Smit LWA; Prince FHM; van Rossum MAJ; Dolman KM; Hoppenreijs EPAH; Ten Cate R; Ursu S; Wedderburn LR; Horneff G; Frosch M; Foell D; Holzinger D
    J Rheumatol; 2018 Apr; 45(4):547-554. PubMed ID: 29335345
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of the 5-aminoimidazole-4-carboxamide ribonucleotide transformylase gene with response to methotrexate in juvenile idiopathic arthritis.
    Hinks A; Moncrieffe H; Martin P; Ursu S; Lal S; Kassoumeri L; Weiler T; Glass DN; Thompson SD; Wedderburn LR; Thomson W
    Ann Rheum Dis; 2011 Aug; 70(8):1395-400. PubMed ID: 21515602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methotrexate Hepatotoxicity in Children with Juvenile Idiopathic Arthritis: A Single-Center Study.
    Yassin NA; Haroon M; Elhamshary A
    Curr Rheumatol Rev; 2021; 17(2):242-246. PubMed ID: 33308133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Health-related quality of life during early aggressive treatment in patients with polyarticular juvenile idiopathic arthritis: results from randomized controlled trial.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Kröger L; Aalto K; Lahdenne P
    Pediatr Rheumatol Online J; 2019 Dec; 17(1):80. PubMed ID: 31842940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate.
    Chickermane PR; Khubchandani RP
    Clin Exp Rheumatol; 2015; 33(2):287-92. PubMed ID: 25738527
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Coping strategies and anxiety in association with methotrexate-induced nausea in juvenile idiopathic arthritis.
    Kyvsgaard N; Thastum M; Mikkelsen TS; Christensen AE; Herlin T
    Rheumatol Int; 2020 Apr; 40(4):591-598. PubMed ID: 31996982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data.
    Davies R; De Cock D; Kearsley-Fleet L; Southwood T; Baildam E; Beresford MW; Foster HE; Thomson W; Ramanan AV; Hyrich KL;
    Rheumatology (Oxford); 2020 Jun; 59(6):1391-1397. PubMed ID: 31605484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Trends towards more active introduction of drug therapy, emphasizing methotrexate and biologic agents, for juvenile idiopathic arthritis.
    Pohjankoski H; Kautiainen H; Lauri JV; Puolakka K; Rantalaiho V
    Clin Rheumatol; 2020 Jan; 39(1):263-268. PubMed ID: 31346886
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H; Minden K; Foeldvari I; Ganser G; Hospach T; Horneff G
    Arthritis Rheumatol; 2014 Sep; 66(9):2580-9. PubMed ID: 24942886
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Time spent in inactive disease before MTX withdrawal is relevant with regard to the flare risk in patients with JIA.
    Klotsche J; Minden K; Niewerth M; Horneff G
    Ann Rheum Dis; 2018 Jul; 77(7):996-1002. PubMed ID: 29453217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolomic Profiling Identifies Exogenous and Microbiota-Derived Metabolites as Markers of Methotrexate Efficacy in Juvenile Idiopathic Arthritis.
    Funk RS; Becker ML
    Front Pharmacol; 2021; 12():768599. PubMed ID: 34955838
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.